Skip to main content
Top
Published in: Journal of Hematology & Oncology 1/2017

Open Access 01-12-2017 | Erratum

Erratum to: Genetic alterations of m6A regulators predict poorer survival in acute myeloid leukemia

Authors: Chau-To Kwok, Amy D. Marshall, John E. J. Rasko, Justin J. L. Wong

Published in: Journal of Hematology & Oncology | Issue 1/2017

Login to get access

Excerpt

The original article [1] contained an error whereby the formatting of Table 1 was not presented correctly; this error has now been corrected.
Table 1
Clinical and molecular characteristics of TCGA AML patients according to the mutation and/or copy number variation status of genes encoding m6A regulatory enzymes
 
Mutation and/or CNV
CNV onlya
Mutation
 
Yes (n = 23)
No (n = 168)
P
Yes (n = 18)
No (n = 168)
P
Yes (n = 5)
No (n = 186)
P
Age
   
0.083
   
0.193
   
0.205
Median (range)
65 (18–81)
57 (21–88)
 
62.5 (18–81)
57 (21–88)
 
65 (45–76)
57.5 (18–88)
 
Sex, no. (%)
   
0.123
   
0.321
   
0.376
Male
16 (8.4)
87 (45.5)
 
12 (6.5)
87 (46.8)
 
4 (2.1)
99 (51.8)
 
Female
7 (3.7)
81 (42.4)
 
6 (3.2)
81 (43.5)
 
1 (0.5)
87 (45.5)
 
BM blast
   
0.072
   
0.038
   
0.915
Median % (range)
60 (30–97)
73 (30–100)
 
54 (30–97)
73 (30–100)
 
75 (33–90)
72 (30–100)
 
WBC, ×103/mm3
   
0.084
   
0.047
   
0.889
Median (range)
5.4 (0.7–202.7)
17.5 (0.4–298.4)
 
5.2 (2.3–101.3)
17.45 (0.4–298.4)
 
14.5 (2.3–101.3)
15.6 (0.4–298.4)
 
Cytogenetic risk, no. (%)
   
<0.0001
   
<0.0001
   
0.483
Favorable
0 (0)
37 (19.4)
 
0 (0)
37 (19.9)
 
0 (0)
37 (19.4)
 
Intermediate
4 (2.1)
105 (55)
 
1 (0.5)
105 (56.5)
 
3 (1.6)
106 (55.5)
 
Unfavorable
19 (9.9)
21 (11)
 
17 (9.1)
21 (11.3)
 
2 (1)
38 (19.9)
 
Missing data
0 (0)
5 (2.6)
 
0 (0)
5 (2.6)
 
0 (0)
5 (2.6)
 
Mutation, no./total no. (%)
 FLT3
1/23 (4.3)
53/168 (31.5)
0.005
0/18 (0)
53/168 (31.5)
0.002
1/5 (20)
53/186 (28.4)
1.000
 NPM1
1/23 (4.3)
51/168 (30)
0.006
0/18 (0)
51/168 (30.3)
0.004
1/5 (20)
51/186 (27.4)
1.000
 DNMT3A
4/23 (17.4)
43/168 (25.6)
0.453
2/18 (11.1)
43/168 (25.6)
0.249
2/5 (40)
45/186 (24.2)
0.598
 IDH1 or IDH2
1/23 (4.3)
34/168 (20.2)
0.084
0/18 (0)
34/168 (20.2)
0.048
1/5 (20)
34/186 (18.3)
1.000
 NRAS or KRAS
3/23 (13)
20/168 (11.9)
0.744
3/18 (16.7)
20/168 (11.9)
0.471
0/5 (0)
23/186 (12.4)
1.000
 RUNX1
2/23 (8.7)
17/168 (10.1)
1.000
0/18 (0)
17/168 (10.1)
0.380
2/5 (40)
17/186 (9.1)
0.078
 TET2
1/23 (4.3)
15/168 (8.9)
0.698
1/18(5.6)
15/168 (8.9)
1.000
0/5 (0)
16/186 (8.6)
1.000
 TP53
15/23 (65.2)
1/168 (0.6)
<0.0001
13/18 (72.2)
1/168 (0.6)
<0.0001
2/5 (40)
14/186 (7.5)
0.057
 CEBPA
2/23 (8.7)
10/168 (6.0)
0.641
2/18 (11.1)
10/168 (6.0)
0.327
0/5 (0)
12/186 (6.5)
1.000
 WT1
0/23 (0)
12/168 (7.1)
0.366
0/18 (0)
12/168 (7.1)
0.610
0/5 (0)
12/186 (6.5)
1.000
 PTPN11
2/23 (8.7)
6/168 (3.6)
0.248
2/18 (11.1)
6/168 (3.6)
0.175
0/5 (0)
8/186 (4.3)
1.000
 KIT
1/23 (4.3)
6/168 (3.6)
0.599
0/18 (20)
6/168 (3.6)
1.000
1/5 (20)
6/186 (3.2)
0.172
Significant P values are in bold
CNV copy number variation, BM bone marrow, WBC white blood cell
aExcluding samples with m6A regulatory gene mutations
Literature
Metadata
Title
Erratum to: Genetic alterations of m6A regulators predict poorer survival in acute myeloid leukemia
Authors
Chau-To Kwok
Amy D. Marshall
John E. J. Rasko
Justin J. L. Wong
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2017
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-017-0419-x

Other articles of this Issue 1/2017

Journal of Hematology & Oncology 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine